

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]**

**Final Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• GlaxoSmithKline (dostarlimab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency for Equality</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• Endometriosis Foundation</li> <li>• Endometriosis UK</li> <li>• Eve Appeal</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Peaches Womb Cancer Trust</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• Wellbeing of Women</li> <li>• Womb Cancer Support UK</li> <li>• Women’s Health Concern</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association of Surgical Oncology</li> <li>• British Geriatrics Society</li> <li>• British Gynaecological Cancer Society</li> <li>• British Institute of Radiology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord (carboplatin, paclitaxel, cisplatin, doxorubicin)</li> <li>• Alliance Healthcare (cyclophosphamide, paclitaxel)</li> <li>• AstraZeneca (durvalumab, olaparib)</li> <li>• Bausch &amp; Lomb (megestrol acetate)</li> <li>• Baxter Healthcare (cyclophosphamide)</li> <li>• Bristol Myers Squibb Pharmaceuticals (paclitaxel)</li> <li>• Consilient Health (carboplatin)</li> <li>• Fresenius Kabi (carboplatin, paclitaxel)</li> <li>• Hospira UK (carboplatin, paclitaxel)</li> </ul>

Final stakeholder list for the evaluation of dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]

Issue date: November 2024

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• British Oncology Pharmacy Association</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Clinical Cytology</li> <li>• British Society for Colposcopy and Cervical Pathology</li> <li>• Cancer Research UK</li> <li>• National Forum of Gynaecological Oncology Nurses</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Obstetricians and Gynaecologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• Johnson &amp; Johnson Innovative Medicine (doxorubicin)</li> <li>• Medac GmbH (doxorubicin)</li> <li>• Merck Sharp &amp; Dohme (pembrolizumab)</li> <li>• Novartis (cisplatin, cyclophosphamide)</li> <li>• Pfizer (carboplatin, paclitaxel, cisplatin, doxorubicin, medroxyprogesterone acetate)</li> <li>• Sandoz (cyclophosphamide)</li> <li>• Seacross Pharmaceuticals (paclitaxel, doxorubicin)</li> <li>• Teva UK (carboplatin, paclitaxel)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.